A phase 3 trial published online on 12 November 2026 found that izalontamab brengitecan lengthened both the time before esophageal cancer worsened and the time patients lived, compared with ordinary chemotherapy. In JAMA, median progression-free survival was 4.17 months with the new drug and 1.97 months with chemotherapy. Median overall survival was 9.79 months and 7.20 months. The research summary walks through the same interim numbers and their limits.

The trial, PANKU-Esophagus01, enrolled adults with recurrent or metastatic esophageal squamous cell carcinoma that had progressed after a first treatment of a PD-1 or PD-L1 inhibitor plus platinum chemotherapy. Investigators screened 704 people and randomly assigned 497, in equal groups, at 80 hospitals in China. Enrollment ran from 19 March 2024 to 1 August 2025. The data cutoff for this analysis was 17 October 2025. The median age was 61, with a range of 34 to 76. Of the 497 patients, 448, or 90.1 percent, were men. Four people who were assigned a treatment did not receive it: 493 were treated.

Izalontamab brengitecan is an antibody-drug conjugate aimed at EGFR and HER3, carrying a topoisomerase I inhibitor the paper calls Ed-04. The assigned dose was 2.5 milligrams per kilogram on days 1 and 8 of a three-week cycle, for 249 patients. The other 248 received a chemotherapy drug their physician chose from irinotecan, paclitaxel or docetaxel, also every three weeks. Patients and doctors knew which treatment was which. Progression-free survival was judged by a blinded independent central review of the scans, using RECIST 1.1. Overall survival was the time until death from any cause.

The hazard ratio for progression or death was 0.50, with a 95 percent confidence interval of 0.40 to 0.63. For death from any cause it was 0.63, with an interval of 0.48 to 0.82. In both cases the log-rank P value was under 0.001. The research summary says 69 of 249 patients on the new drug had a confirmed tumor response, 27.7 percent, against 23 of 248 on chemotherapy, 9.3 percent.

What the benefit does not settle

Grade 3 or higher treatment-related adverse events occurred in 212 of 249 patients on izalontamab brengitecan, 85.1 percent, and in 147 of 248 on chemotherapy, 59.3 percent. The abstract says those events were predominantly hematologic. It does not give a count of deaths caused by treatment.

The journal's own summary says the follow-up at this interim look is short, that every site was in China, and that people with brain metastases were excluded. Biomarker results for EGFR and HER3 were not yet available. The research summary names Baili-Bio (Chengdu) Pharmaceutical Co., Ltd as the funder. The registry record lists the experimental drug as BL-B01D1, with Sichuan Baili Pharmaceutical Co., Ltd as the lead sponsor and Baili-Bio as a collaborator. It shows the same enrollment of 497, an open-label design, a primary completion date of 17 October 2025, and a study completion date of June 2027. The status on that page is active, not recruiting. The authors describe the drug as a new second-line option for this group of patients in China. The paper is an interim report, not a regulatory approval, and it does not say the drug is available as routine care.